Clinical trials: Monoclonal Antibody
Solid Tumor
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors
This is a phase I trial with BYON4228, a humanized monoclonal antibody (mAb) directed against signal regulatory protein (SIRP)α in solid tumors, alone and in combination with pembrolizumab.
- Trial name
- NCT06932952
- Testing
- BYON4228 + Pembrolizumab
- Where
- 6 sites in Belgium, Spain and 1 more
- Volunteers
- 7 people
- Sponsor
- Byondis B.V.
HIV Infections
Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of the Monoclonal Antibody PGT121.414.LS Administered Alone and in Combination With VRC07-523LS Via Intravenous or Subcutaneous Infusions in Healthy, HIV-uninfected Adult Participants
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of the monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS via intravenous or…
- Trial name
- NCT04212091
- Testing
- PGT121.414.LS, VRC07-523LS
- Where
- 5 sites in United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Anti-CD20 Monoclonal Antibody, BTK Inhibitors
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia
This study aims to utilize anti-CD20 monoclonal antibodies to eliminate peripheral B cells and reduce the mechanism of autoantibody production, as well as combine the mechanism of BTK inhibitors (BTKi) blocking the B cell…
- Conditions
- Anti-CD20 Monoclonal Antibody, BTK Inhibitors, Immune Thrombocytopenia (ITP), Autoimmune Hemolytic Anemia (AIHA)
- Trial name
- NCT07574073
- Testing
- Anti-CD20 monoclonal antibody and the BTK inhibitor
- Volunteers
- 30 people
- Sponsor
- Qi deng
Rheumatoid Arthritis
Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis
The primary objective of this study is to assess the safety (by collecting adverse events and serious adverse events) of adalimumab administered every other week to patients with moderately to severly active rheumatoid arthritis…
- Trial name
- CanAct (NCT00649545)
- Testing
- adalimumab
- Sponsor
- Abbott
Neoadjuvant Immunotherapy of Cisplatin-ineligible High Risk Upper Urinary Tract Urothelial Carcinoma
Neoadjuvant PD-1 Monoclonal Antibody in Cisplatin-ineligible High Risk Upper Tract Urothelial Carcinoma
Neoadjuvant therapy of cisplatin-based chemotherapy has been proved to improve prognosis of muscle invasive UTUC patients in several studies.
- Trial name
- NCT04672330
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 16 people
- Sponsor
- RenJi Hospital
Leukemia, Lymphoma
Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia
RATIONALE: Radiolabeled monoclonal antibodies can locate cancer cells and deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00004107
- Testing
- filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Immune Thrombocytopenia
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
- Trial name
- NCT07104565
- Testing
- INCA000585
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 56 people
- Sponsor
- Incyte Corporation
Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular
Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma
The purpose of this study is to determine whether combining pixantrone (BBR 2778, INN name pending) with the monoclonal antibody rituximab, leads to an increase in the period of patients' remission, compared to rituximab alone.
- Conditions
- Lymphoma, Follicular, Lymphoma, Mixed-Cell, Follicular, Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Low-Grade
- Trial name
- NCT00060671
- Testing
- rituximab, Pixantrone (BBR 2778)
- Where
- 38 sites in United States
- Volunteers
- 800 people
- Sponsor
- CTI BioPharma
Solid Tumors
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose)…
- Trial name
- NCT02660034
- Testing
- Tislelizumab, Pamiparib
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 229 people
- Sponsor
- BeiGene
Healthy Volunteers
Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux
Background Colorectal cancer (CRC) is one of the most common human malignant tumors. The incidence and mortality of colorectal cancer in our country are on the rise.
- Trial name
- NCT03881787
- Testing
- anti-EGFR monoclonal antibody, Cetuximab injection
- Where
- 2 sites in China
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Dragonboat Biopharmaceutical Company Limited
CD20 Positive B Cell Non-Hodgkin's Lymphoma
B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
It's the first-in-human study of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection (B001). The main purpose of this study is to explore the safety and tolerance of B001 for patients with CD20 positive B-cell non…
- Trial name
- NCT03332121
- Testing
- B001
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Anthrax
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Primary: To compare the safety profile of a single intravenous administration of AVP-21D9 as compared with Placebo Secondary: To evaluate the pharmacokinetics (PK) of a single intravenous administration of AVP-21D9 To evaluate…
- Trial name
- NCT01202695
- Testing
- AVP-21D9
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Testicular Cancer
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
The goal of this clinical research study is to learn if 2 cycles of high-dose chemotherapy can help to control germ-cell tumors.
- Trial name
- NCT00936936
- Testing
- Gemcitabine, Docetaxel, Melphalan
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- M.D. Anderson Cancer Center
Monoclonal Gammopathy, Tuberculosis
Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis
The purpose of this study is to determine whether the monoclonal protein in patients with tuberculosis and monoclonal gammopathy has anti-tuberculous activity, and whether genes coding their monoclonal proteins show…
- Trial name
- NCT00173264
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Advanced Cancer
Doxil, Bevacizumab and Temsirolimus Trial
The goal of this clinical research study is to learn the highest safe doses of the combination of Doxil (liposomal doxorubicin), Avastin (bevacizumab), and Torisel (Temsirolimus) that can be given to patients with advanced cancer…
- Trial name
- NCT00761644
- Testing
- Doxil, Bevacizumab, Temsirolimus
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Headache (Migraine)
Work-related Burden Changes, Quantified with HEADWORK, Among Individuals Treated with Migraine Preventive Therapies.
Migraine is one of the leading causes of disability worldwide among the population under 50. It's economic indirect burden is mostly determined by reduction of work productivity both by absenteeism and presenteeism.
- Trial name
- NCT06812299
- Where
- 3 sites in Italy
- Volunteers
- 175 people
- Sponsor
- IRCCS National Neurological Institute "C. Mondino" Foundation
Neoplasms
Study of IMC-11F8 in Participants With Advanced Solid Tumors
This study is to establish the safety and pharmacokinetic (PK) profile of IMC-11F8, administered either: (1) in a 3-week cycle; or (2) in a 2-week cycle to Japanese participants with advanced solid tumors who have not responded…
- Trial name
- NCT01088464
- Testing
- IMC-11F8
- Where
- Japan
- Volunteers
- 15 people
- Sponsor
- Eli Lilly and Company
Systemic Lupus Erythematosus
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)
- Trial name
- BLOSSOM (NCT05835310)
- Testing
- Anifrolumab
- Where
- 103 sites in United States, Argentina and 15 more
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer
The primary objectives of this study is to assess the safety and tolerability of intravenously (i.v.) administered 186 Rhenium-isotope (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of…
- Trial name
- NCT02204059
- Testing
- hMAb BIWA 4
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Graft-vs-Host Disease
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD).
- Trial name
- NCT00032279
- Testing
- Visilizumab
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.